SCHEMBL22389307

SCHEMBL22389307

CC(=O)NC1C(OCCOCCN)OC(COC(=O)c2ccccc2)C(O)C1OC(=O)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.42
▸ LMNA P02545 3/20 0.42
▸ POLB P06746 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ SSTR5 P35346 6/20 0.40
▸ SSTR3 P32745 5/20 0.40
▸ SSTR2 P30874 3/20 0.40
▸ SSTR1 P30872 1/20 0.40
▸ SSTR4 P31391 1/20 0.40
▸ LGALS9 O00182 1/20 0.38
▸ LGALS1 P09382 1/20 0.38
▸ LGALS3 P17931 1/20 0.38
▸ LGALS7; LGALS7B P47929 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.36
▸ MCHR1 Q99705 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19781228 0.93 LMNA (0.49) KMT2ALMNAPOLBMEN1USP2
SCHEMBL19781108 0.85 USP2 (0.43) KMT2APOLBMEN1USP2CYP2C9
SCHEMBL19769332 0.85 KMT2A (0.38) KMT2ALMNAPOLBMEN1USP2
SCHEMBL19613777 0.83 LMNA (0.44) KMT2ALMNAPOLBMEN1USP2
SCHEMBL14978161 0.81 USP2 (0.50) KMT2APOLBMEN1USP2CYP2C9
SCHEMBL21101101 0.81 USP2 (0.50) KMT2APOLBMEN1USP2CYP2C9
SCHEMBL10177584 0.81 USP2 (0.50) KMT2APOLBMEN1USP2CYP2C9
SCHEMBL10906318 0.81 MCHR1 (0.46) KMT2ALMNAPOLBSSTR5SSTR3
SCHEMBL19786845 0.81 LMNA (0.53) KMT2ALMNAPOLBMEN1USP2
SCHEMBL13786400 0.79 LMNA (0.52) KMT2ALMNAPOLBMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159458-A1 SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES AM CHEMICALS LLC (US) 2023-05-25 — — US disclosed
US-20200277260-A1 SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES AM CHEMICALS LLC (US) 2020-09-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159458-A1 SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES NCL, PAICS, RTCB KMT2A 1607/4885LMNA 2437/4885POLB 14/4885
US-20200277260-A1 SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES NCL, PAICS, RTCB KMT2A 1607/4885LMNA 2437/4885POLB 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback